多玛医药科技

Doma Biopharmaceutical (Suzhou) Co., Ltd. is an innovative biotechnology company and life science incubation platform founded in September 2021 and headquartered in BioBAY, Suzhou, China. Backed by major shareholders including Biocytogen, the company leverages advanced antibody discovery platforms, such as the RenLite common light chain mouse platform, to develop a proprietary pipeline of next-generation therapeutics, with a primary focus on bispecific antibody-drug conjugates (BsADCs) for oncology. Doma Biopharmaceutical operates under a unique empowerment-based incubation model, co-founding and supporting specialized subsidiaries like Xadcera (focused on BsADCs) and Xaicure (focused on small molecule targeted therapies). Its lead clinical assets include DM001 (an EGFR/TROP2 BsADC), DM002 (a HER3/MUC1-C BsADC), and DM005 (an EGFR/c-MET BsADC), all of which are currently undergoing global Phase I/II clinical trials for various advanced solid tumors.